Markets:

Overview

News

Currencies

International

Treasuries

TG Therapeutics, Inc. - Common Stock (NQ:TGTX)

28.73 -1.77 (-5.81%)

Streaming Delayed Price Updated: 3:21 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about TG Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

TG Therapeutics TGTX Q3 2025 Earnings Transcript ↗

November 27, 2025

TG Therapeutics TGTX Q3 2025 Earnings Transcript

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 11, 2025

Via Benzinga

TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results ↗

November 10, 2025

Roche presented "unprecedented" test results for its multiple sclerosis treatment, putting pressure on rival TG Therapeutics.

Via Investor's Business Daily

Hussman Sells Off All 21,000 CHKP Shares Valued At $4.65 Million ↗

November 03, 2025

Hussman Sells Off All 21,000 CHKP Shares Valued At $4.65 Million

Via The Motley Fool

TG Therapeutics Stock Soars After Company Ups Guidance For Multiple Sclerosis Drug ↗

November 03, 2025

Via Stocktwits

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

Earnings Preview For TG Therapeutics ↗

October 31, 2025

Via Benzinga

TG Therapeutics Board Authorizes New $100M Share Repurchase Program ↗

September 03, 2025

Via Stocktwits

10 Health Care Stocks Whale Activity In Today's Session ↗

November 03, 2025

Via Benzinga

Top Stocks With Earnings This Week: Joby, IonQ, AMD and More ↗

November 03, 2025

Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday.

Via Benzinga

Earnings Scheduled For August 4, 2025 ↗

August 04, 2025

Via Benzinga

What's Next: TG Therapeutics's Earnings Preview ↗

August 01, 2025

Via Benzinga

Highly Watched TG Therapeutics Smashes Profit Views — With A Caveat ↗

November 03, 2025

TG Therapeutics stock rose early Monday on better-than-expected earnings.

Via Investor's Business Daily

Topics Earnings

Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity ↗

October 16, 2025

William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline.

Via Benzinga

TG THERAPEUTICS INC (NASDAQ:TGTX) Shows High Growth Momentum and Technical Breakout Setup ↗

October 07, 2025

TG Therapeutics (TGTX) shows explosive EPS growth up to 1,300% and strong sales momentum. With a perfect 10 technical rating and a bullish chart setup, it's a high-growth stock to watch.

Via Chartmill

10 Health Care Stocks Whale Activity In Today's Session ↗

October 01, 2025

Via Benzinga

TG Therapeutics CEO Voices Strong Conviction In Briumvi With New $100 Million Buyback ↗

September 03, 2025

TG Therapeutics' stock rose after completing a $100 million buyback and approving another $100 million plan, reinforcing confidence in Briumvi and growth prospects.

Via Benzinga

TG Therapeutics Stock Tumbles 15% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug ↗

August 04, 2025

The company raised its Briumvi U.S. net product revenue target to $570 million to $575 million for the full year 2025, up from its previous guidance of $560 million.

Via Stocktwits

Topics Earnings

Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results ↗

August 04, 2025

Via Benzinga

Briumvi's Strong Sales Can't Stop TG Therapeutics Stock Slide ↗

August 04, 2025

TG Therapeutics missed Q2 earnings and revenue expectations but raised its 2025 Briumvi sales guidance following strong global growth.

Via Benzinga

TG Therapeutics Q2 Revenue Up 91% ↗

August 04, 2025

Via The Motley Fool

Topics Intellectual Property

Why Top 3% Stock TG Therapeutics Crashed Despite Raising Its 2025 Outlook ↗

August 04, 2025

The company makes a multiple sclerosis treatment called Briumvi that rivals a drug from Roche.

Via Investor's Business Daily

Traders are paying attention to the gapping stocks in Monday's session. ↗

August 04, 2025

Let's delve into the US markets on Monday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Via Chartmill

TG Therapeutics Inc (NASDAQ:TGTX) Reports Mixed Q2 2025 Results, Raises Full-Year BRIUMVI Revenue Guidance ↗

August 04, 2025

TG Therapeutics reported mixed Q2 2025 results, missing revenue and EPS estimates but raising full-year BRIUMVI sales guidance. Shares dipped slightly as investors weighed the outlook.

Via Chartmill

TG THERAPEUTICS INC (NASDAQ:TGTX) – A High Growth Momentum Stock with Strong Technical Setup ↗

July 17, 2025

TG THERAPEUTICS INC (NASDAQ:TGTX) shows strong earnings momentum and a bullish technical setup, making it a candidate for high-growth investors. The stock has solid revenue growth, improving margins,...

Via Chartmill

TG THERAPEUTICS INC (NASDAQ:TGTX) - A High-Growth Stock Meeting Minervini's Trend Template ↗

July 12, 2025

TG Therapeutics (TGTX) meets Minervini's Trend Template with strong technicals and high-growth fundamentals, including 1,300% EPS growth and 90% revenue expansion. A breakout above $37.27 could signal...

Via Chartmill

Cramer Backs This Mining Giant After $1.6B Bet ↗

July 01, 2025

Jim Cramer recommends buying Rio Tinto due to its high yield. TG Therapeutics is also a buy, with strong first-quarter sales and potential for market share growth.

Via Benzinga

TG THERAPEUTICS INC (NASDAQ:TGTX) - A High Growth Momentum Stock with Strong Technical Setup ↗

June 25, 2025

TG Therapeutics (TGTX) shows strong earnings momentum with 142% EPS growth and a bullish technical setup, making it a candidate for high-growth investors.

Via Chartmill

TG Therapeutics Boosts Retail Sentiment With Q1 Revenue Beat Even As Stock Tumbles On Profit Miss, Conservative Outlook ↗

May 05, 2025

Investors are optimistic about the company’s prospects, particularly in the multiple sclerosis market, despite challenges from competitors.

Via Stocktwits

TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show ↗

May 05, 2025

TG Therapeutics posts Q1 profit and nearly doubles revenue, driven by rising Briumvi sales and higher full-year guidance for 2025.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.